Patents Assigned to Quark Biotech, Inc.
-
Publication number: 20090258021Abstract: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.Type: ApplicationFiled: August 20, 2007Publication date: October 15, 2009Applicant: Quark Biotech, Inc.Inventors: Paz EINAT, Orit Segev, Rami Skaliter, Elena Feinstein, Alexander Faerman, Aviva Samach
-
Publication number: 20080249038Abstract: The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system.Type: ApplicationFiled: October 6, 2004Publication date: October 9, 2008Applicant: Quark Biotech, Inc.Inventors: Elena Feinstein, Igor Mett, Svetlana Gorodin, Michael Shtutman
-
Patent number: 7259253Abstract: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.Type: GrantFiled: June 4, 2003Date of Patent: August 21, 2007Assignee: Quark Biotech, Inc.Inventors: Paz Einat, Orit Segev, Rami Skaliter, Elena Feinstein, Alexander Faerman, Aviva Samach
-
Patent number: 7202211Abstract: The present invention relates to use of Narp inhibitor in order to promote or enhance recovery from ischemic events, particularly focal ischemia of the central nervous system, as well as for preventing or diminishing chronic degenerative changes.Type: GrantFiled: February 20, 2003Date of Patent: April 10, 2007Assignees: Astellas Pharma Inc., Quark Biotech, Inc.Inventors: Alexander Faerman, Sylvia G. Kachalsky, Gregory Hirsch Idelson
-
Publication number: 20070072244Abstract: This application is directed to a process of identifying a compound capable of modulating activity of a human ENDO180 receptor that comprises the steps of measuring the binding of the ENDO180 receptor to an interactor with which the ENDO180 receptor interacts specifically in vivo, in the absence or presence of a compound, and determining whether the binding of the ENDO180 receptor to the interactor is affected by the compound. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis. This application also relates to the use of ENDO180 modulators in treatment of disease.Type: ApplicationFiled: November 16, 2005Publication date: March 29, 2007Applicant: QUARK BIOTECH, INC.Inventors: Orna Mor, Elena Feinstein, Alexander Faerman
-
Publication number: 20060241290Abstract: There are provided polynucleotides that are modulated by hypoxic conditions. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are also disclosed. The presence of hypoxia or a hypoxia-associated pathology may be diagnosed by screening for the presence of at least one polynucleotide having the nucleic acid sequence according to the present invention. Methods of regulating hypoxia associated pathologies are also provided.Type: ApplicationFiled: May 25, 2006Publication date: October 26, 2006Applicant: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter, Elena Feinstein, Aviv Regev
-
Patent number: 7074895Abstract: There are provided polynucleotides which are modulated by hypoxic conditions. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are also disclosed. The presence of hypoxia or a hypoxia-associated pathology may be diagnosed by screening for the presence of at least one polynucleotide having the nucleic acid sequence according to the present invention. Methods of regulating hypoxia associated pathologies are also provided.Type: GrantFiled: March 9, 2001Date of Patent: July 11, 2006Assignee: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter, Elena Feinstein, Aviv Regev
-
Patent number: 6998232Abstract: There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of chemical compound are also provided.Type: GrantFiled: April 4, 2001Date of Patent: February 14, 2006Assignee: Quark Biotech, Inc.Inventors: Elena Feinstein, Orna Mor
-
Patent number: 6986988Abstract: A method for enrichment of natural antisense mRNA which involves hybridization of cDNA obtained from sense RNA with cDNA obtained from antisense RNA, followed by DNA polymerase treatment of the sense-antisense hybrid DNA molecule. A natural antisense library can be generated by cloning of sense-antisense hybrid DNA molecules in a vector.Type: GrantFiled: April 11, 2001Date of Patent: January 17, 2006Assignee: Quark Biotech, Inc.Inventors: Shlomit Gilad, Paz Einat, Avital Grossman
-
Publication number: 20050004065Abstract: The polynucleotide sequence of the 2-2-83 gene encodes the 2-2-83 protein. Hypoxic-associated pathologies may be regulated by administering an effective amount of a polynucleotide or protein of the present invention, or a direct or indirect biologically active product of enzymatic activity of the protein. Tumorigenesis may be inhibited by inhibiting the enzymatic activity of the protein of the present invention. The presence of a hypoxia-associated pathology may be diagnosed by screening for the reduced expression of the 2-2-83 gene.Type: ApplicationFiled: June 2, 2004Publication date: January 6, 2005Applicant: Quark Biotech, Inc.Inventors: Elena Feinstein, Paz Einat, Rami Skaliter
-
Patent number: 6833237Abstract: Genes and the proteins encoded thereby that are involved in stroke response and/or are regulated by FK506 are disclosed. These genes were discovered using in vivo or in vitro stroke models by determining which genes were differentially upregulated or downregulated upon treatment of the model with FK506. They were also found by a functional assay of genes specifically selected for conferring to cells resistance to hypoxia, dopamine or glutamate treatment. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are disclosed. Methods for screening for compounds capable of regulating the genes and proteins of the invention are also disclosed.Type: GrantFiled: December 12, 2001Date of Patent: December 21, 2004Assignees: Quark Biotech, Inc., Fujitsawa Pharmaceutical Co., Ltd.Inventors: Elena Feinstein, Igor Mett, Sylvia G. Kachalsky, Svetlana Gorodin
-
Publication number: 20040229886Abstract: This invention provides a method for the treatment of a subject in need of treatment for osteoarthritis comprising administering to said subject an amount of an inhibitor of spermidine biosynthesis sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention also provides the use of an inhibitor of spermidine biosynthesis in the treatment of a subject in need of treatment of osteoarthritis in an amount sufficient to effect a substantial inhibition of spermidine biosynthesis This invention further provides a method of preparing a therapeutic composition for the treatment of a subject in need of a treatment for osteoarthritis and the invention further provides a method identifying an inhibitor of spermidine biosynthesis, whereby the inhibitor is a spermidine synthesis inhibitor.Type: ApplicationFiled: February 24, 2004Publication date: November 18, 2004Applicant: Quark Biotech, Inc. & Shionogi Co., Ltd.Inventors: Dganit Bar, Elena Feinstein, Orit Segev
-
Publication number: 20040180336Abstract: A method for enrichment of natural antisense mRNA which involves hybridization of cDNA obtained from sense RNA with cDNA obtained from antisense RNA, followed by DNA polymerase treatment of the sense-antisense hybrid DNA molecule. A natural antisense library can be generated by cloning of sense-antisense hybrid DNA molecules in a vector.Type: ApplicationFiled: April 11, 2001Publication date: September 16, 2004Applicant: Quark Biotech, Inc.;Inventors: Shlomit Gilad, Paz Einat, Avital Grossman
-
Patent number: 6740738Abstract: According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to hypoxic conditions in a patient in need of such treatment.Type: GrantFiled: December 23, 2002Date of Patent: May 25, 2004Assignee: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter
-
Publication number: 20040053301Abstract: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.Type: ApplicationFiled: June 4, 2003Publication date: March 18, 2004Applicant: QUARK BIOTECH, INC.Inventors: Paz Einat, Orit Segev, Rami Skaliter, Elena Feinstein, Alexander Faerman, Aviva Samach
-
Patent number: 6696454Abstract: This invention provides a method for the treatment of a subject in need of treatment for osteoarthritis comprising administering to said subject an amount of an inhibitor of spermidine biosynthesis sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention also provides the use of an inhibitor of spermidine biosynthesis in the treatment of a subject in need of treatment of osteoarthritis in an amount sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention further provides a method of preparing a therapeutic composition for the treatment of a subject in need of a treatment for osteoarthritis and the invention further provides a method of identifying an inhibitor of spermidine biosynthesis, whereby the inhibitor is a spermidine synthase inhibitor.Type: GrantFiled: December 12, 2001Date of Patent: February 24, 2004Assignees: Quark Biotech, Inc., Shionogi & Co., Ltd.Inventors: Dganit Bar, Elena Feinstein, Orit Segev
-
Publication number: 20030124116Abstract: According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to hypoxic conditions in a patient in need of such treatment.Type: ApplicationFiled: December 23, 2002Publication date: July 3, 2003Applicant: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter
-
Publication number: 20030104973Abstract: According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to ischemic or hypoxic conditions in a patient in need of such treatment.Type: ApplicationFiled: March 6, 2002Publication date: June 5, 2003Applicant: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter
-
Patent number: 6555667Abstract: Neuroleukin (SEQ ID NO:8) has been discovered to be hypoxia regulated. Furthermore, it serves as an astrocyte motility factor. Astrocyte motility can be inhibited by a neuroleukin inhibitor.Type: GrantFiled: June 28, 2000Date of Patent: April 29, 2003Assignee: Quark Biotech, Inc.Inventors: Paz Einat, Rami Skaliter
-
Patent number: 6544741Abstract: This invention provides methods for constructing a normalized cDNA library, constructing a low copy gene library, preparing a probe from a biological sample and a kit for constructing a normalized cDNA library.Type: GrantFiled: July 12, 2000Date of Patent: April 8, 2003Assignee: Quark Biotech, Inc.Inventor: Raja C. Mugasimangalam